Technology
Health
Pharmaceutical

MEI Pharma

$3.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (1.97%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MEI Pharma and other stocks, options, ETFs, and crypto commission-free!

About

MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Read More Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Employees
32
Headquarters
San Diego, California
Founded
2000
Market Cap
221.68M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
306.21K
High Today
$3.15
Low Today
$3.01
Open Price
$3.06
Volume
36.42K
52 Week High
$5.14
52 Week Low
$1.82

Collections

Technology
Health
Pharmaceutical
Medical
Cancer Prevention
US
North America

News

Yahoo FinanceMay 9

MEI Pharma Reports Third Quarter Fiscal Year 2019 Results and Operational Highlights

SAN DIEGO, May 9, 2019 /PRNewswire/ -- MEI Pharma, Inc. (MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its third quarter ended March 31, 2019. "As progress continues across our pipeline of four clinical-stage oncology candidates, including two in clinical studies that may support future submissions for FDA marketing approval, we are particularly excited with the expanding data set from the ME-401 intermittent dosing schedule as it conti...

116
NasdaqMay 1

Earnings Preview: MEI Pharma (MEIP) Q3 Earnings Expected to Decline

MEI Pharma (MEIP) is expected to deliver a year-over-year decline in earnings on higher revenues when i t report s results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

119

Earnings

-$0.36
-$0.16
$0.04
$0.24
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Aug 29, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.